Published originally by Logos Technologies prior to Instem ownership, included here for information purposes
Comprehensive Clinical Development Selects ALPHADAS®, Logos Technologies Early Phase EDC System for its 430 Early Phase Beds
It is announced today that Comprehensive Clinical Development (CCD) has entered into an agreement with Logos Technologies’ for its market leading, early phase, e-source data capture system and site automation software suite, ALPHADAS which gives clinical research sites unsurpassed tools to accelerate and streamline their clinical trial operations and service. ALPHADAS will be used in all of CCD 430 Phase I/BE beds across their three state of the art early phase research facilities, located in Tacoma (WA), Fort Myers (FL) and Miramar (FL) USA.
“We are delighted that CCD has chosen ALPHADAS for their eSource data collection needs. The proven benefits and cost savings that ALPHADAS provides to organisations such as CCD are immense and we are very excited to be working with them to provide them with a quick Return on their Investment,” said Giles Wilson, BEng, CEO of Logos Technologies Inc. “CCD join an ever increasing number of companies that are choosing ALPHADAS for their early phase EDC needs. For a company such as them to choose ALPHADAS is a significant endorsement to the quality of ALPHADAS and our proven expertise in early phase EDC”.
CCD Early Phase has been a leader in providing early phase investigative services since 1994 with outstanding expertise in rapid study startup, complex study methodologies and medical technologies, and special populations.
ALPHADAS, is an e-Source, pro-active EDC automation system designed specifically for early phase clinical trials which has achieved great success. It is a market proven solution that offers a depth of functionality other systems cannot provide. Logos Technologies continues to invest in ALPHADAS, even further increasing its performance and functionality making it the ‘System of Choice’ for early phase EDC.
Comprehensive Clinical Development is a strategic clinical research partner providing a full range of clinical services in various therapeutic areas with an outstanding record for consistently delivering quality and success on time and within budget. Comprehensive holds a solid track record of collecting early efficacy data across various patient populations, and offers distinct capabilities in clinical research.